Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESSOR-1: Mezigdomide vs Pomalidomide in Relapsed or Refractory Multiple Myeloma
NCT05519085Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2022
- Primary completion
- Jan 2027
- Modality
- Molecular Glues
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free Survival at 5 years. Started Sep 2022; status: recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05519085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519085.